Skip navigation
Pay Bill Portals
Our Tests
Oncology
TESTS
Signatera™ – Residual Disease Test (MRD)
Latitude™ – Tissue Free MRD
Altera™ – Tumor Genomic profile
Empower™ – Hereditary Cancer Test
FOR PATIENTS
Signatera™ Patient Information
Altera™ Patient Information
Empower™ Patient Information
Pricing and Billing Information
FOR CLINICIANS
Signatera™ Clinician Information
Altera™ Clinician Information
Empower™ Clinician Information
Oncology Portal
Signatera™ Research Pipeline
Altera™ Gene Table
Organ Health
TESTS
Prospera™ Kidney – Transplant Assessment
Prospera™ Heart – Transplant Assessment
Prospera™ Lung – Transplant Assessment
Renasight™ – Kidney Gene Panel
FOR PATIENTS
Prospera™ for Kidney Patients
Prospera™ for Heart Patients
Prospera™ for Lung Patients
Renasight™ Patient Information
Pricing and Billing Information
FOR CLINICIANS
Prospera™ for Kidney Clinician
Renasight™ Clinician Information
Renasight™ Gene Conditions List
Organ Health Portal
Women’s Health
TESTS
Horizon™ – Advanced Carrier Screening
Panorama™ – Noninvasive Prenatal Testing (NIPT)
Empower™ – Hereditary Cancer Test
Vistara™ – Single-Gene NIPT
Anora™ – Miscarriage Test
Vasistera™ – Limited Noninvasive Prenatal Testing (NIPT)
Spectrum™ – Preimplantation Genetics
FOR PATIENTS
Pricing and Billing Information
Women’s Health Portal
FOR CLINICIANS
NateraConnect Provider Portal
Horizon™ Conditions List
NEVA for Empower – Natera’s Educational Virtual Assistant
Our Services
Oncology
SERVICES
NateraCore Services
Pharma Partnership
Real-World Data
EMR Integration
FOR PATIENTS
Schedule a Genetic Information Session
Pricing and Billing Information
Contact Us
FOR CLINICIANS
Schedule Session With Client Services
Oncology Portal
Order a Test Kit
Contact Us
Organ Health
SERVICES
NateraCore Services
ProReach
EMR Integration
Pharma Services
FOR PATIENTS
Schedule a Genetic Information Session
Order a Renasight Kit
Contact Us
Pricing and Billing Information
FOR CLINCIANS
Organ Health Portal
Order a Renasight Kit
Contact Us
Women’s Health
SERVICES
NateraCore Services
Constellation
EMR Integration
FOR PATIENTS
Schedule a Genetic Information Session
Pricing and Billing Information
Women’s Health Portal
Contact Us
FOR CLINICIANS
Order Tests and Track Status on NateraConnect
View Patient Results on NateraConnect
Contact Us
Patient Resources
Oncology
LEARN
Signatera™
Altera™
Empower™
View All Patient Resources
EXISTING PATIENTS
Schedule a Genetic Information Session
Schedule Blood Draw (Existing Patients)
Pricing and Billing Information
CONNECT
Contact Us
Organ Health
LEARN
Prospera™
Renasight™
View All Patient Resources
EXISTING PATIENTS
Schedule Blood Draw (Existing Patients)
Schedule a Genetic Information Session
Pricing and Billing Information
CONNECT
Contact Us
Women’s Health
LEARN
Horizon™
Panorama™
Empower™
Vistara™
Anora™
Spectrum™
View All Patient Resources
EXISTING PATIENTS
Schedule a Genetic Information Session
Schedule Blood Draw (Existing Patients – USA)
Schedule Blood Draw (Existing Patients – Canada)
Pricing and Billing Information
Women’s Health Portal
CONNECT
Contact Us
Clinical Resources
Oncology
CLINICAL RESOURCES
Signatera™
Signatera™ Publications
Altera™
Empower™
View All Clinician Resources
RESEARCH STUDIES
Signatera™ Research Pipeline
Natera Sponsored Trials
CONNECT
Oncology Portal
Contact Us
Organ Health
CLINICAL RESOURCES
Organ Health Publications
Prospera™
Renasight™
View All Clinician Resources
RESEARCH STUDIES
ProActive Study
PEDAL Study
Trifecta Study
MOTR Study
CONNECT
Organ Health Portal
Contact Us
Women’s Health
CLINICAL RESOURCES
Women’s Health Publications
Horizon™
Panorama™
Empower™
Vistara™
Anora™
Spectrum™
Natera Academy Provider Education Hub
View All Clinician Resources
RESEARCH STUDIES
CONNECT
Contact Us
Company
About Us
Our People
Our Technology
News
Events
Careers
Investor Relations
Sustainability
Contact Us
Click to show search bar
Natera Acquires Foresight Diagnostics, Accelerating Leadership in MRD Detection
Learn More
Protect Health and Inform Earlier, More Targeted Interventions

Natera’s cell-free DNA tests help inform more personalized health care decisions.

Test

Measure fetal, tumor, or donor cfDNA at the molecular level with a noninvasive test.

Know

Identify risk of disease, detect recurrence, and understand treatment responses.

Decide

Make more-informed health decisions for individualized care.

Dedicated to Oncology, Women’s Health, and Organ Health
Oncology Tests

Characterize tumors, anticipate risk, and evaluate treatment response earlier than traditional tools. Hear Jeff’s story.

Learn More

Women’s Health Tests

Identify risk of severe genetic conditions to help families prepare and inform early intervention that can improve outcomes. Hear Corrine’s story.

Learn More

Organ Health Tests

Detect organ injury early and inform treatment strategy to improve transplant health. Hear Gigi’s story.

Learn More

Innovating with Integrity
Natera advances molecular diagnostics with integrity and scientific rigor, and supports integration of information provided by our tests into health care decision making. Our tests are clinically validated in over 300 peer-reviewed publications with over 3 million patients studied.

We participated in the largest prospective studies to date in molecular diagnostics in oncology (CIRCULATE), women’s health (SMART), and organ health (Trifecta). We meet or exceed applicable industry and regulatory standards for all of our tests to deliver high-quality results, and have processed over 12 million tests in our CAP/CLIA‑certified labs.

We have more than 150 medical professionals on staff who provide expert support to help make our test results clear and easy to understand.

Creating a World of Possibilities

Natera advances molecular diagnostics with integrity and scientific rigor, and supports integration of information provided by our tests into health care decision making.

Natera News

December 22, 2025

Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Read More

December 18, 2025

Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer
Read More

December 16, 2025

I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer
Read More

View All News

Looking for more information?
Let us help you find your way
I am a 
select
clinician
patient
researcher
 looking for tests and resources for 
select
oncology
organ health
women's health
 Show me
Our Tests
Oncology
Organ Health
Women’s Health
Our Services
Oncology Core
Organ Health Core
Women’s Health Core
Patient Resources
Resource Library
Pricing & Billing
Pay Bill
Patient Portals
Clinical Resources
Resource Library
Provider Portals
Company
About Us
Our People
Our Technology
News
Events
Careers
Investor Relations
Sustainability at Natera
Contact
Contact Us
Schedule Blood Draw (Existing Patients – USA)
Schedule Blood Draw (Existing Patients – Canada)
Schedule a Genetic Information Session
 
 
 
 
Natera Licenses
IT Security Compliance
Notice of Data Collection for California Residents
Do Not Share My Personal Information
Your Privacy Choices
HIPAA Notice of Privacy Practices
Privacy Policy
Terms of Use

Designed by Elegant Themes | Powered by WordPress

The tests described have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test. The tests have not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified. © 2025 Natera, Inc. All Rights Reserved.